Jefferies Financial Group Inc. Buys 1,361,803 Shares of Xencor, Inc. $XNCR

Key Points

• Jefferies Financial Group increased its Xencor stake by 189% in the third quarter, buying 1,361,803 shares. It held 2,082,243 shares—about 2.8% of Xencor—valued at roughly $52 million.
• Xencor reported quarterly EPS of $0.50, beating the consensus estimate of a $0.33 loss, and revenue of $116.52 million versus $63 million expected. Revenue rose 453.3% year over year.
• Analysts’ average rating was Moderate Buy, with an average price target of $42.22; shares opened at $39.97, near their 52-week high of $40.60.

Jefferies Financial Group Inc. increased its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 189.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,082,243 shares of the biopharmaceutical company's stock after purchasing an additional 1,361,803 shares during the period. Jefferies Financial Group Inc. owned approximately 2.80% of Xencor worth $51,952,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in XNCR. GAMMA Investing LLC lifted its stake in Xencor by 15.5% in the third quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 572 shares during the period. Allworth Financial LP boosted its holdings in Xencor by 23.2% during the second quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 646 shares during the last quarter. Pinnacle Wealth Planning Services Inc. grew its position in shares of Xencor by 31.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 5,804 shares of the biopharmaceutical company's stock worth $145,000 after buying an additional 1,373 shares during the period. WINTON GROUP Ltd grew its position in shares of Xencor by 1.5% during the 2nd quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company's stock worth $1,711,000 after buying an additional 1,534 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Xencor by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,567 shares of the biopharmaceutical company's stock worth $339,000 after buying an additional 1,767 shares during the period.

Xencor Trading Up 1.5%

NASDAQ:XNCR opened at $39.97 on Thursday. The business's 50-day simple moving average is $26.91 and its 200-day simple moving average is $17.85. Xencor, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $40.60.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.83. Xencor had a negative return on equity of 21.28% and a negative net margin of 58.79%. The business had revenue of $116.52 million during the quarter, compared to analysts' expectations of $63.00 million. During the same period in the prior year, the business earned ($0.08) EPS. Xencor's revenue for the quarter was up 453.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Xencor, Inc. will post -2.61 EPS for the current year.

Wall Street Analysts Forecast Growth

XNCR has been the topic of several recent analyst reports. Bank of America lifted their price objective on shares of Xencor from $20.00 to $26.00 and gave the stock a "neutral" rating in a research note on Monday, September 21st. Wedbush upped their target price on shares of Xencor from $30.00 to $45.00 and gave the company an "outperform" rating in a research note on Tuesday, October 27th. Wells Fargo & Company upped their target price on shares of Xencor from $30.00 to $44.00 and gave the company an "overweight" rating in a research note on Tuesday, October 27th. Wall Street Zen upgraded shares of Xencor from a "hold" rating to a "buy" rating in a report on Saturday, November 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xencor in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $42.22.

Xencor Profile

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company's XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.